Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Liposomal Bupivacaine (Exparel ® ) Plus 0.5% Bupivacaine HCL Versus 0.5% Bupivacaine HCL for Interscalene Nerve Block (ISB) for Patients Undergoing Total Shoulder Arthroplasty(TSA)

NCT03913091 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT03913091
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03913091 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Liposomal Bupivacaine (Exparel ® ) Plus 0.5% Bupivacaine HCL Versus 0.5% Bupivacaine HCL for Interscalene Nerve Block (ISB) for Patients Undergoing Total Shoulder Arthroplasty(TSA)
Lead sponsor
NYU Langone Health
Phase
Phase 4
Overall status
Completed
Start date
March 1, 2019
Completion date
January 19, 2021
Enrollment
184 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

shoulder pain